Skip to main content
Erschienen in: Der Internist 8/2014

01.08.2014 | Schwerpunkt

Therapie chronisch-entzündlicher Darmerkrankungen

Standards, Kontroversen und Perspektiven

verfasst von: Prof. Dr. K. Herrlinger, K. Fellermann, E.F. Stange

Erschienen in: Die Innere Medizin | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Morbus Crohn und Colitis ulcerosa sind die häufigsten chronisch-entzündlichen Darmerkrankungen. Ihre Behandlung wird zunehmend komplex und gerade bei komplizierten Krankheitsverläufen auch individualisierter. Dieser Beitrag gibt einen umfassenden Überblick über die Verlaufsformen und die Standardtherapie beider Erkrankungen. Weiterhin wird auf aktuelle Kontroversen wie die frühe Immunsuppression und Immunmodulation, aber auch auf neue Therapieziele wie die Mukosaheilung eingegangen. Schließlich wird ein Ausblick auf zukünftige Therapieoptionen gegeben. Hier steht insbesondere Vedolizumab, ein Antikörper gegen das darmspezifische α4β7-Integrin, im Fokus.
Literatur
1.
Zurück zum Zitat Hoffmann JC, Preiss JC, Autschbach F et al (2008) Clinical practice guideline on diagnosis and treatment of Crohn’s disease. Z Gastroenterol 46:1094–1146 Hoffmann JC, Preiss JC, Autschbach F et al (2008) Clinical practice guideline on diagnosis and treatment of Crohn’s disease. Z Gastroenterol 46:1094–1146
2.
Zurück zum Zitat Dignass A, Preiss JC, Aust DE et al (2011) Updated German guideline on diagnosis and treatment of ulcerative colitis. Z Gastroenterol 49:1276–1341 Dignass A, Preiss JC, Aust DE et al (2011) Updated German guideline on diagnosis and treatment of ulcerative colitis. Z Gastroenterol 49:1276–1341
3.
Zurück zum Zitat Dignass A, Van Assche G, Lindsay JO et al (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 4:28–62 Dignass A, Van Assche G, Lindsay JO et al (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 4:28–62
4.
Zurück zum Zitat Dignass A, Lindsay JO, Sturm A et al (2012) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 6:991–1030 Dignass A, Lindsay JO, Sturm A et al (2012) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 6:991–1030
5.
Zurück zum Zitat Solberg IC, Vatn MH, Høie O et al (2007) Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 5:1430–1438PubMedCrossRef Solberg IC, Vatn MH, Høie O et al (2007) Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 5:1430–1438PubMedCrossRef
6.
Zurück zum Zitat Tromm A, Bunganič I, Tomsová E et al (2011) Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn’s disease. Gastroenterology 140:425–434PubMedCrossRef Tromm A, Bunganič I, Tomsová E et al (2011) Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn’s disease. Gastroenterology 140:425–434PubMedCrossRef
7.
Zurück zum Zitat Targan SR, Hanauer SB, Deventer SJ van et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med 337:1029–1035 Targan SR, Hanauer SB, Deventer SJ van et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med 337:1029–1035
8.
Zurück zum Zitat Hanauer SB, Sandborn WJ, Rutgeerts P et al (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130:323–333PubMedCrossRef Hanauer SB, Sandborn WJ, Rutgeerts P et al (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130:323–333PubMedCrossRef
9.
Zurück zum Zitat Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405 Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405
10.
Zurück zum Zitat Colombel JF, Schwartz DA, Sandborn WJ et al (2009) Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut 58:940–948PubMedCentralPubMedCrossRef Colombel JF, Schwartz DA, Sandborn WJ et al (2009) Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut 58:940–948PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Lémann M, Mary JY, Duclos B et al (2006) Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology 130:1054–1061PubMedCrossRef Lémann M, Mary JY, Duclos B et al (2006) Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology 130:1054–1061PubMedCrossRef
12.
Zurück zum Zitat Lémann M, Mary JY, Colombel JF et al (2005) A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology 128:1812–1818PubMedCrossRef Lémann M, Mary JY, Colombel JF et al (2005) A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology 128:1812–1818PubMedCrossRef
13.
Zurück zum Zitat Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549PubMedCrossRef Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549PubMedCrossRef
14.
Zurück zum Zitat Colombel JF, Sandborn WJ, Rutgeerts P et al (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132:52–65PubMedCrossRef Colombel JF, Sandborn WJ, Rutgeerts P et al (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132:52–65PubMedCrossRef
15.
Zurück zum Zitat Solberg IC, Lygren I, Jahnsen J et al (2009) Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 44:431–440PubMedCrossRef Solberg IC, Lygren I, Jahnsen J et al (2009) Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 44:431–440PubMedCrossRef
16.
Zurück zum Zitat Regueiro M, Loftus EV Jr, Steinhart AH et al (2006) Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 12:979–994PubMedCrossRef Regueiro M, Loftus EV Jr, Steinhart AH et al (2006) Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 12:979–994PubMedCrossRef
17.
Zurück zum Zitat Marteau P, Probert CS, Lindgren S et al (2005) Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54:960–965PubMedCentralPubMedCrossRef Marteau P, Probert CS, Lindgren S et al (2005) Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54:960–965PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Sandborn WJ, Kamm MA, Lichtenstein GR et al (2007) MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized double-blind, placebo-controlled trials. Aliment Pharmacol Ther 26:205–215PubMedCrossRef Sandborn WJ, Kamm MA, Lichtenstein GR et al (2007) MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized double-blind, placebo-controlled trials. Aliment Pharmacol Ther 26:205–215PubMedCrossRef
19.
Zurück zum Zitat Kruis W, Kiudelis G, Rácz I et al (2009) Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 58:233–240PubMedCentralPubMedCrossRef Kruis W, Kiudelis G, Rácz I et al (2009) Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 58:233–240PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Faubion WA Jr, Loftus EV Jr, Harmsen WS et al (2001) The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121:255–260PubMedCrossRef Faubion WA Jr, Loftus EV Jr, Harmsen WS et al (2001) The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121:255–260PubMedCrossRef
22.
Zurück zum Zitat Laharie D, Bourreille A, Branche J et al (2012) Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 380:1909–1915PubMedCrossRef Laharie D, Bourreille A, Branche J et al (2012) Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 380:1909–1915PubMedCrossRef
23.
Zurück zum Zitat Panaccione R, Ghosh S, Middleton S et al (2014) Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146:392–400PubMedCrossRef Panaccione R, Ghosh S, Middleton S et al (2014) Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146:392–400PubMedCrossRef
24.
Zurück zum Zitat D’Haens G, Baert F, Assche G van et al (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 371:660–667CrossRef D’Haens G, Baert F, Assche G van et al (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 371:660–667CrossRef
25.
Zurück zum Zitat Colombel JF, Sandborn WJ, Reinisch W et al (2010) Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 362:1383–1395 Colombel JF, Sandborn WJ, Reinisch W et al (2010) Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 362:1383–1395
26.
Zurück zum Zitat Van Assche G, Magdelaine-Beuzelin C, D’Haens G et al (2008) Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134:1861–1868CrossRef Van Assche G, Magdelaine-Beuzelin C, D’Haens G et al (2008) Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134:1861–1868CrossRef
27.
Zurück zum Zitat Louis E, Mary JY, Vernier-Massouille G et al (2012) Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142:63–70PubMedCrossRef Louis E, Mary JY, Vernier-Massouille G et al (2012) Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142:63–70PubMedCrossRef
28.
Zurück zum Zitat Cosnes J, Bourrier A, Laharie D et al (2013) Early administration of azathioprine vs conventional management of Crohn’s disease: a randomized controlled trial. Gastroenterology 145:758–765PubMedCrossRef Cosnes J, Bourrier A, Laharie D et al (2013) Early administration of azathioprine vs conventional management of Crohn’s disease: a randomized controlled trial. Gastroenterology 145:758–765PubMedCrossRef
29.
Zurück zum Zitat Panés J, López-Sanromán A, Bermejo F et al (2013) Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology 145:766–774PubMedCrossRef Panés J, López-Sanromán A, Bermejo F et al (2013) Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology 145:766–774PubMedCrossRef
30.
Zurück zum Zitat Ardizzone S, Cassinotti A, Duca P et al (2011) Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 9:483–489PubMedCrossRef Ardizzone S, Cassinotti A, Duca P et al (2011) Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 9:483–489PubMedCrossRef
31.
Zurück zum Zitat Sandborn WJ, Feagan BG, Marano C et al (2014) Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:85–95PubMedCrossRef Sandborn WJ, Feagan BG, Marano C et al (2014) Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:85–95PubMedCrossRef
32.
Zurück zum Zitat Sandborn WJ, Feagan BG, Marano C et al (2014) Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:96–109PubMedCrossRef Sandborn WJ, Feagan BG, Marano C et al (2014) Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:96–109PubMedCrossRef
33.
Zurück zum Zitat Sandborn WJ, Feagan BG, Rutgeerts P et al (2013) Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 369:711–721 Sandborn WJ, Feagan BG, Rutgeerts P et al (2013) Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 369:711–721
34.
Zurück zum Zitat Feagan BG, Rutgeerts P, Sands BE et al (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369:699–710 Feagan BG, Rutgeerts P, Sands BE et al (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369:699–710
35.
Zurück zum Zitat Danese S (2012) New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 61:918–932PubMedCrossRef Danese S (2012) New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 61:918–932PubMedCrossRef
Metadaten
Titel
Therapie chronisch-entzündlicher Darmerkrankungen
Standards, Kontroversen und Perspektiven
verfasst von
Prof. Dr. K. Herrlinger
K. Fellermann
E.F. Stange
Publikationsdatum
01.08.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Innere Medizin / Ausgabe 8/2014
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI
https://doi.org/10.1007/s00108-013-3442-1

Weitere Artikel der Ausgabe 8/2014

Der Internist 8/2014 Zur Ausgabe

Mitteilungen der DGIM

Mitteilungen der DGIM

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.